Daniel P. Cahill

Massachusetts General Hospital — United States

Medicine · Health Sciences

76h-index34.1kcitations819works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(406), Brain Metastases and Treatment(112), Cancer, Hypoxia, and Metabolism(92), Meningioma and schwannoma management(70), Cancer Immunotherapy and Biomarkers(62)

Publications813 total

Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial
Nature Medicine·2026Open Access
A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment
The Lancet Oncology·2025· 1 cited
A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making
The Lancet Oncology·2025· 1 cited
Local therapy with hypoxia-targeting radiopharmaceutical [64Cu]Cu-ATSM in high-grade glioma patient-derived xenograft models
Radiotherapy and Oncology·2025
10166-CB-4 Evaluation of Radiation Response and 2-Hydroxyglutarate Suppression by IDH Inhibition in IDH Mutant Glioma Cells
Neuro-Oncology Advances·2025Open Access
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group
The Lancet Oncology·2025· 4 citedOpen Access
Supplementary Table S1 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
2025Open Access
Supplementary Methods S1 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
2025Open Access
Supplementary Figures S1-S17 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
2025Open Access
Supplementary Table S2 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
2025Open Access
Multi-Institutional Assessment of Circulating Cell-Free DNA in Cerebrospinal Fluid Facilitates Central Nervous System Lymphoma Diagnosis and Treatment Initiation
Neurosurgery·2025
TMOD-16. Generation of orthotopic patient-derived xenografts from progressive oligodendroglioma without TMZ-induced hypermutation
Neuro-Oncology·2025
CNSC-33. ELECTROPHYSIOLOGIC SIGNATURES OF TUMOR INFILTRATION ACROSS GLIOMA SUBTYPES ON INTRACRANIAL EEG
Neuro-Oncology·2025
EXTH-81. Developing cell-state guided chimeric antigen receptor (CAR)-T cell therapies for IDH-mutant glioma
Neuro-Oncology·2025
SURG-100. The favorable associations between age and supramaximal resection with outcome in glioblastoma – a report of the RANO resect group
Neuro-Oncology·2025Open Access
SURG-79. A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicenter, retrospective study with external validation by the RANO resect group
Neuro-Oncology·2025
IMG-125. Differentiating tumor progression from pseudoprogression in glioma patients using MR elastography
Neuro-Oncology·2025Open Access
RADT-85. PHASE II STUDY OF PROTON THERAPY FOR LOWER GRADE GLIOMAS: SURVIVAL AND TOXICITY OUTCOMES
Neuro-Oncology·2025Open Access
CTNI-30. ALLIANCE A071601: PHASE II TRIAL OF BRAF/MEK INHIBITION IN RECURRENT PAPILLARY CRANIOPHARYNGIOMAS
Neuro-Oncology·2025
CTNI-62. A SURGICAL WINDOW-OF-OPPORTUNITY TRIAL OF NIRAPARIB IN RECURRENT IDH-MUTANT GLIOMAS
Neuro-Oncology·2025Open Access
page 1 of 41Next →

Frequent Co-authors

David N. Louis(16), Tracy T. Batchelor(15), William T. Curry(14), Hiroaki Wakimoto(11), Priscilla K. Brastianos(10), A. John Iafrate(10), Brian V. Nahed(9), Mario L. Suvà(8), B Bernstein(7), S. Andrew(7), Matthew P. Frosch(6), Orit Rozenblatt–Rosen(6), Anoop P. Patel(6), Keith L. Ligon(6), Itay Tirosh(6), Kenneth W. Kinzler(6), Bert Vogelstein(6), Aviv Regev(5), Christoph Lengauer(5), Scott L. Carter(5)